Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 32

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 32
---
>

Assuming
we sell all Units offered pursuant to this prospectus, we estimate the net proceeds
from this offering will be approximately $15.5 million, based on an assumed combined public
offering price of $5.09 per Unit with Depositary Shares (the last reported sale price of
our Depositary Shares on the NASDAQ Capital Market on December 4, 2025) and $5.0899 per Unit
with Pre-Funded Warrants (the last reported sale price of our Depositary Shares on the NASDAQ
Capital Market on December 4, 2025, minus $0.0001), after deducting placement agent fees
and estimated offering expenses payable by us as described in “Plan of Distribution,”
and excluding the proceeds, if any, from the cash exercise of the Pre-Funded Warrants and
Series L Warrants sold in this offering.

We intend to use the net proceeds
from this offering to fund our development programs, for working capital and other general corporate purposes.

The allocation of the net
proceeds of the offering represents our estimates based upon our current plans and assumptions regarding industry and general economic
conditions, our future revenues and expenditures.

As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon completion of this offering, or the
amount we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds will vary depending
on numerous factors, including the relative success and cost of our research and development programs, our ability to gain access to additional
financing, and other factors described under “Risk Factors” in this prospectus and in our Annual Report on Form 20-F for the
year ended December 31, 2024. As a result, our management will have broad discretion in the application of the net proceeds, and investors
will be relying on our management’s judgment regarding the application of the net proceeds of this offering.

Pending the application of
the net proceeds as described above, we will hold the net proceeds from this offering in short-term, interest-bearing, securities.

| 21 |

<div align='center'>DIVIDEND POLICY</div>

Since inception, we have never
declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on our Ordinary Shares or the
Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund